Over the years, the pharmaceutical industry has invested billions of dollars in research to develop new drugs and improve the quality of the drugs produced, but a large number of drugs have been depleted due to toxicity and side effects that emerged in late clinical trials. Scientists often use animal models to identify new compounds and predict the toxicity profile of drug compounds. However, the inability of animal models to accurately reflect human pathophysiology has hindered the development of drugs. Therefore the development and improvement of cell-based assays and disease models for drug screening and drug toxicity assessment is critical to the development of safe and effective drug candidates.
Cell reprogramming techniques can help address the current impediments to drug development. This technology allows access to patient-specific hiPSCs, enabling in vitro disease modeling and drug discovery processes at a low cost. In addition, patient-specific iPSCs carry all the genetic information of the patient, analysis based on these cells makes it possible to identify subgroups of patients showing specific drug adverse reaction profiles, thus providing a promising new approach to demographic-based drug discovery and toxicology.
Fig.1 Combined approach involving animal models and iPSC technology. (Inoue, 2011)
Solutions for Drug Development based on Cell Reprogramming
Cell reprogramming technologies allow exploration of disease mechanisms and screening for new therapeutic molecular targets, and provide opportunities for drug development as well as validation. Researchers at Creative Bioarray are focusing on the development of the iPSC technology and providing scientifically sound solutions for our clients to integrate this technology into existing drug development paradigms.
- Cell Reprogramming for Drug Screening
- Cell Reprogramming for Drug Toxicology Assessment
We have been working to continuously improve the efficiency of cell reprogramming and developing iPSC-based drug screening technologies to help identify new therapeutic approaches for patients.
We can provide researchers with unlimited quantities of stable quality iPSCs to test drug toxicity in vitro, thus avoiding the harm of drug toxicity to patients in Phase I clinical trials.
Applications
- Neurological Diseases Drug Discovery
- Cardiovascular Diseases Drug Discovery
- Ophthalmologic Diseases Drug Discovery
- Infectious Diseases Drug Discovery
- Orphan Drug Discovery
- Cancer Drug Discovery
Advantages
- Innovative and rigorous scientific spirit
- Professional and efficient technical guidance
- Open and respectful communication
- Flexible customer-centric service
As a leading service provider in cell reprogramming, Creative Bioarray provides expert guidance and scientific solutions for our clients' projects in proof-of-concept studies for drug development. Our advanced iPSC technology platform also provides a powerful in vitro platform for drug development for a wide range of diseases. If you would like to learn more about our services, please feel free to contact us.
Reference
- Inoue, H.; Yamanaka, S. The use of induced pluripotent stem cells in drug development. Clinical Pharmacology & Therapeutics. 2011, 89(5): 655-661.